BenzingaAugust 10, 2026 at 9:45 AM NY2 Months Ago
Truist Securities Maintains Buy on Cytokinetics, Raises Price Target to $112
Truist Securities analyst Srikripa Devarakonda maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $106 to $112.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
